Loading
A phase 1/2 trial of Niraparib in advanced solid tumours, run by GlaxoSmithKline, active and no longer recruiting.
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors is a phase 1/2 interventional study registered as NCT06077877 by GlaxoSmithKline, with 42 participants enrolled, started 2023-10-24 and due to reach its primary completion in 2026-06-30. Interventions recorded: GSK4524101 and Niraparib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Niraparib, GSK, PARP inhibitors and the tag pipeline.
Shares Niraparib, GSK, PARP inhibitors and the tag pipeline.
Shares GSK, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares GSK, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares GSK, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares GSK, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PARP inhibitors, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PARP inhibitors, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/